Pfizer Inc (PFE)

Cash conversion cycle

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Days of inventory on hand (DOH)	days	180.81	173.99	146.01	148.27	130.59	126.10	150.56	112.98	94.30	99.64	98.45	99.13	106.77	130.57	195.48	259.63	290.57	346.33	316.74	302.48
Days of sales outstanding (DSO)	days	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Number of days of payables	days	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Cash conversion cycle	days	180.81	173.99	146.01	148.27	130.59	126.10	150.56	112.98	94.30	99.64	98.45	99.13	106.77	130.57	195.48	259.63	290.57	346.33	316.74	302.48

December 31, 2024 calculation

Cash conversion cycle = DOH + DSO – Number of days of payables
= 180.81 + — – —
= 180.81

Pfizer Inc's cash conversion cycle, which represents the number of days it takes for the company to convert its investments in inventory and other resources into cash receipts from sales, has fluctuated over the reported periods.

The cash conversion cycle for Pfizer has shown a decreasing trend from March 31, 2020, to June 30, 2021, indicating an improvement in efficiency in managing its working capital. This implies that Pfizer was able to reduce the time it takes to convert its investments into cash, which may suggest effective inventory management and collection processes during this period.

However, from September 30, 2021, to December 31, 2024, there was a fluctuating pattern in the cash conversion cycle with periods of increase and decrease. This could indicate potential challenges in managing working capital efficiently, leading to longer cash conversion cycles in certain quarters.

Overall, Pfizer's cash conversion cycle has shown variability over time, and it is important for the company to continue monitoring and managing its working capital effectively to ensure optimal cash flow and liquidity.